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Purpose: Alpha-fetoprotein (AFP) is a prognostic marker for hepatocellular carcinoma (HCC). We investigated the prognostic 
value of AFP levels in patients who achieved complete response (CR) to transarterial chemoembolization (TACE) for HCC.
Materials and Methods: Between 2005 and 2018, 890 patients with HCC who achieved a CR to TACE were recruited. An AFP re-
sponder was defined as a patient who showed elevated levels of AFP (>10 ng/mL) during TACE, but showed normalization or a 
>50% reduction in AFP levels after achieving a CR.
Results: Among the recruited patients, 569 (63.9%) with naïve HCC and 321 (36.1%) with recurrent HCC after complete resection 
were treated. Before TACE, 305 (34.3%) patients had multiple tumors, 219 (24.6%) had a maximal tumor size >3 cm, and 22 (2.5%) 
had portal vein tumor thrombosis. The median AFP level after achieving a CR was 6.36 ng/mL. After a CR, 473 (53.1%) patients 
experienced recurrence, and 417 (46.9%) died [median progression-free survival (PFS) and overall survival (OS) of 16.3 and 62.8 
months, respectively]. High AFP levels at CR (>20 ng/mL) were independently associated with a shorter PFS [hazard ratio 
(HR)=1.403] and OS (HR=1.284), together with tumor multiplicity at TACE (HR=1.518 and 1.666, respectively). AFP non-respond-
ers at CR (76.2%, n=359 of 471) showed a shorter PFS (median 10.5 months vs. 15.5 months, HR=1.375) and OS (median 41.4 
months vs. 61.8 months, HR=1.424) than AFP responders (all p=0.001).
Conclusion: High AFP levels and AFP non-responders were independently associated with poor outcomes after TACE. AFP holds 
clinical implications for detailed risk stratification upon achieving a CR after TACE.
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INTRODUCTION
A significant portion of patients with intrahepatic hepatocel-
lular carcinoma (HCC) are not suitable candidates for curative 
treatments, such as local ablation, surgical resection, and liver 
transplantation, due to decreased liver function, large tumor 
burden, and vascular invasion.1-3 The majority of these patients 
receive single or multiple rounds of transarterial chemoembo-
lization (TACE), which takes advantage of the hypervascular-
ized nature of HCC with increased arterial enhancement and 
rapid washout on imaging studies.1,3-5
Recent studies have shown that response evaluation accord-
ing to enhancement criteria, such as European Association for 
the Study of the Liver and modified response evaluation crite-
ria in solid tumor (mRECIST) criteria, holds prognostic impli-
cations in patients with HCC,1,6 and a complete response (CR) 
has been found to be an independent predictor of overall sur-
vival (OS) among patients with inoperable HCC after TACE.7-9 
Thus, to ensure better outcomes, achieving a CR after TACE 
according to enhancement criteria is most important in pa-
tients with HCC.5-7 However, CR achievement does not always 
guarantee total necrosis of the tumor or the absence of small 
intrahepatic metastases, and thus, a considerable portion of 
these patients experience recurrence that needs further treat-
ments.8,10-12
Serum alpha-fetoprotein (AFP) is a well-recognized bio-
marker that is overexpressed in the majority of human HCCs. 
AFP is usually low in adult serum because mature hepatocytes 
usually lose their ability to synthesize AFP. However, liver can-
cer cells can regain the ability to produce AFP, a phenomenon 
that is known to be correlated with tumor burden and poor 
differentiation.13,14 Previous studies have revealed that AFP lev-
els are associated with prognosis after loco-regional treatment 
of HCC,15 and post-treatment changes in AFP levels are also 
known to be good prognostic factors for HCC, even after 
TACE.16,17 However, the prognostic value of AFP in patients 
who achieve a CR after TACE has not been investigated.
Therefore, we aimed to investigate whether changes in AFP 
levels between TACE and achieving a CR and absolute AFP 




Patients who achieved a CR after one or more sessions of TACE 
as the first-line treatment were recruited using a retrospective 
review of patient databases at nine tertiary medical centers in 
Korea (Severance Hospital, Yonsei University College of Medi-
cine; Samsung Medical Center, Sungkyunkwan University 
School of Medicine; Ewha Womans University College of Medi-
cine; CHA Bundang Medical Center, CHA University; Ajou 
University School of Medicine; Inje University Haeundae Paik 
Hospital; Pusan National University Yangsan Hospital; Yeung-
nam University Medical Centre; and Kyungpook National Uni-
versity). The study population included patients treated for na-
ïve HCC and recurrent HCC after curative resection.
The exclusion criteria were 1) under 19 years of age; 2) met-
astatic liver mass from other cancers; 3) co-existing extrahe-
patic tumor; 4) no measurement of AFP before TACE and at 
the time of confirming CR; 5) significant extrahepatic disease 
representing an imminent life threatening outcome; 6) uncon-
trolled medical comorbidity; 7) mortality of unknown cause 
that was not due to illness; 8) mortality that was absolutely due 
to procedure-related complications, rather than liver failure 
after TACE; 9) follow-up loss within 2 months after the TACE 
date after which the first CR was achieved; and 10) additional 
local therapies, such as radiofrequency ablation and intraar-
terial chemoinfusion, before the first CR.
The study protocol was in accordance with the 1975 Decla-
ration of Helsinki guidelines. The need for written informed 
consent was waived because of the retrospective nature of this 
study. The Institutional Review Board, Yonsei University Health 




HCC was diagnosed histologically or clinically according to the 
guidelines proposed by the Korea Liver Cancer Study Group. 
A positive finding for typical HCC on dynamic computed to-
mography or magnetic resonance imaging (MRI) was de-
scribed as increased arterial enhancement followed by de-
creased enhancement, compared to the liver (washout), in the 
portal or equilibrium phases.4 Recurrent HCC was defined as 
the presence of newly appeared lesions strongly suspected for 
HCC rather than other malignancies in imaging studies after 
CR confirmation. 
Barcelona Clinic Liver Cancer (BCLC) stage was classified 
based on the extent of the primary lesion, performance status 
according to each patient’s medical record, and portal vein tu-
mor thrombosis.18 Since this study excluded patients with ex-
trahepatic lesions, patients with BCLC stage C were classified 
according to portal vein tumor thrombosis and performance 
status.
Treatment modality
Before TACE, angiography of the superior mesenteric and he-
patic arteries was performed to assess portal vein patency, 
vascular anatomy, and tumor vascularity. During TACE, a mix-
ture of 5 mL of iodized oil contrast medium, lipiodol, and 25–
75 mg of adriamycin was infused selectively at the level of a 
sub-segmental branch (if possible) or a segmental branch of 
the feeding arteries. Thereafter, embolization was performed 
using gelatin sponge particles. In cases of residual or recurrent 
viable tumor seen on liver dynamic computed tomography 
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(LDCT) or MRI, sequential TACE was scheduled at 6- to 8-week 
intervals and on an ‘on-demand’ basis until CR achievement, 
provided that the patients’ clinical and laboratory findings per-
mitted this and if there was no evidence of extrahepatic spread 
or major portal vein invasion without appearance of extrahe-
patic metastases, major portal vein invasion, or deterioration 
in the clinical status or laboratory values.
Assessment of treatment responses using mRECIST
The treatment responses were assessed 3–4 weeks after TACE 
sessions using LDCT or MRI. In cases where there was no via-
ble portion of the tumor after TACE, patients underwent LDCT 
or MRI within 2–3 months until recurrence. Two or more inde-
pendent radiologists in each institution analyzed the images to 
minimize the possibility of false categorizations.
The mRECIST guidelines, which define viable tumors ac-
cording to the uptake of contrast material in the arterial phase 
of dynamic CT, were used in this study; tumors retaining io-
dized oil, as well as necrotic lesions without intratumoral arte-
rial enhancement, were regarded as necrotized tumor foci. Up 
to two target lesions (selected in the order of the maximum 
baseline diameter to represent the entire tumor burden) in the 
liver were assessed using one-dimensional measurements ac-
cording to previous investigations on the ‘optimal number of 
target lesions’ for the mRECIST guidelines on HCC treated with 
TACE.6 This study focused on the acquisition of a CR, defined 
by complete disappearance of viable lesions after TACE, and 
recurrence or progression, defined as a newly developed le-
sion from previously treated lesions or other sites.
Definitions
The time point of CR achievement after TACE was set as the 
baseline to investigate the prognostic value of AFP upon 
achieving a CR after TACE. The time point of TACE (at TACE) 
was defined as the time point of the last TACE just before ob-
taining a CR. An AFP responder was defined as a patient with 
elevated AFP levels (>10 ng/mL) at TACE, but with >50% re-
duction in AFP or AFP ≤10 ng/mL at CR. In contrast, AFP non-
responders were defined as patients with AFP >10 ng/mL at 
TACE, ≤50% reduction in AFP, and elevated AFP >10 ng/mL at 
CR.
Statistical analysis
Considering the time interval between TACE and CR achieve-
ment, progression-free survival (PFS) was assessed from the 
date of achieving CR after TACE until the date of first recur-
rence or death. OS was calculated as the time interval between 
TACE and either death or final follow-up. PFS and OS were es-
timated by the Kaplan-Meier analysis, and survival differenc-
es between subgroups were assessed by log rank test. The Cox 
proportional hazards model was used for univariate and mul-
tivariate analyses of PFS and OS. All variables found to be sig-
nificant in univariate analysis were included in the multivari-
ate model. A p<0.05 was considered statistically significant, 
with a confidence interval (CI) of 95%. Statistical analyses were 
conducted using IBM SPSS Statistics software, version 25.0 
(IBM Corp., Armonk, NY, USA).
RESULTS
Patient characteristics
From 2005 to 2018, a total of 890 patients with naïve or recur-
rent HCC after curative surgery who achieved a CR after single 
or multiple sessions of TACE as a front-line therapy were re-
Table 1. Baseline Characteristics of the Study Population after Achiev-
ing a Complete Response after TACE (n=890)
Variables Values
Demographic variables
Age (yr) 61.4 (55.0–69.4)
>70 208 (32.4)
Male gender 695 (78.1)
Body mass index (kg/m2) 24.0 (22.1–25.9)
Hypertension 248 (27.9)
Diabetes mellitus 185 (20.8)
Viral infection 750 (84.3)
Hepatitis B virus/Hepatitis C virus 621/135
Alcoholic etiology 103 (11.6)
Liver cirrhosis 671 (75.4)
Laboratory variables
Aspartate aminotransferase (IU/L) 37.0 (28.0–53.0)
Alanine aminotransferase (IU/L) 25.0 (16.0–41.0)
Serum albumin (g/dL) 3.9 (3.5–4.2)
Total bilirubin (mg/dL) 0.8 (0.6–1.1)
Prothrombin time (INR) 1.09 (1.02–1.17)
AFP (ng/mL) 6.36 (3.13–15.64)
>10 303 (34.0)
>20 196 (22.0)
Tumor variables at TACE
AFP (ng/mL) 11.85 (4.10–80.30)
>10 471 (52.9)
>20 366 (41.1)
Recurrent HCC after complete resection 321 (36.1)




253 (28.4)/472 (53.0)/ 
112 (12.6)/53 (6.0)
Multiple tumors 305 (34.3)
Maximal tumor size (cm) 2.0 (1.4–2.9)
>3 cm 219 (24.6)
Portal vein tumor thrombosis 22 (2.5)
TACE, transarterial chemoembolization; AFP, alpha-fetoprotein; INR, interna-
tional normalized ratio; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic 
Liver Cancer.
Values are expressed as a median (interquartile range) or n (%).
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viewed in this retrospective, multicenter, cohort study.
Baseline characteristics of the patients with a CR are sum-
marized in Table 1. The median age of 695 (78.1%) male pa-
tients and 195 (21.9%) female patients was 61.4 [interquartile 
range (IQR), 55.0–69.4] years. Among all patients, 569 (63.9%) 
with naïve HCC and 321 (36.1%) with recurrent HCC after com-
plete resection were treated with TACE. Hepatitis B virus in-
fection was identified in 621 (69.8%) patients, and 671 (75.4%) 
patients were diagnosed with liver cirrhosis. At TACE, 165 
(18.6%) patients had intermediate and advanced stage HCC 
according to BCLC. Tumor multiplicity was identified in 305 
(34.3%) patients, and the maximal tumor size was over 3 cm in 
219 (24.6%) patients. A total of 53 (6.0%) patients had BCLC 
stage C HCC due to portal vein tumor thrombosis (n=22) and 
poor performance status (n=29).
AFP levels and changes after CR achievement 
following TACE
The median AFP level was 11.85 (IQR, 4.10–80.30) ng/mL, and 
elevated AFP levels (>10 ng/mL) were identified in 471 (52.9%) 
patients at TACE. The median AFP level at CR was 6.36 (IQR, 
3.13–15.64) ng/mL, and the AFP value at CR was still elevated 
>10 ng/mL in 303 (34.0%) patients and >20 ng/mL in 196 (22.0%) 
patients. Of 471 patients with elevated AFP at TACE (>10 ng/mL), 
112 (23.8%) patients were AFP non-responders (Tables 1 and 2).
Prognosis after CR
During the median follow-up period of 35.2 (IQR 20.5–67.5) 
months after TACE, 630 (70.8%) patients experienced HCC re-
currence, and 417 (46.9%) patients died. Median PFS was 16.3 
(IQR 7.9–41.6) months, and median OS was 62.8 (IQR 34.9–
103.6). Among 471 patients with AFP >10 ng/mL at TACE, me-
dian PFS was 13.7 (IQR 7.3–36.5) months, and median OS was 
56.1 (IQR 31.5–95.6) months (Table 2 and Supplementary Fig. 1, 
only online).
Better outcomes in patients with low AFP values and 
AFP responders at CR
Among the study population, patients with an elevated AFP 
value >20 ng/mL at CR (n=196, 22.0%) showed significantly 
shorter PFS (median 11.2 months vs. 17.7 months, p<0.001) 
and OS (median 50.5 months vs. 70.2 months, p=0.003) than 
those with AFP below 20 ng/mL at CR. In the subgroup with an 
elevated AFP level >10 ng/mL at TACE (n=471), AFP respond-
ers showed a significantly longer PFS (median 15.5  months vs. 
10.5 months, p=0.001) and OS (median 61.8 months vs. 41.4 
months, p=0.001) than non-responders (Table 2 and Fig. 1).
Independent predictors of shorter PFS at CR
Univariate analysis revealed that four variables were signifi-
cantly associated with shorter PFS: BCLC stage B and C (vs. 
stage 0 and A), multiple tumors, low serum albumin, and an 
AFP value >20 ng/mL at CR (Supplementary Table 1, only on-
line). Multivariate analysis showed that AFP >20 ng/mL at CR 
[hazard ratio (HR)=1.403] and tumor multiplicity (HR=1.518) 
were significantly associated with shorter PFS (Table 3). In a 
subgroup with an AFP level >10 ng/mL at TACE (n=471), AFP 
non-responders were independently associated with shorter 
PFS (HR=1.375), together with BCLC stage B/C (vs. 0/A, HR= 
1.377) and tumor multiplicity (HR=1.317) (Table 3 and Supple-
mentary Table 1, only online).
Independent predictors of shorter OS at CR
An elevated AFP value (>20 ng/mL) at CR significantly pre-
dicted a shorter OS in univariate analysis with several other 
variables (Supplementary Table 2, only online). Multivariate 
analysis showed that AFP >20 ng/mL at CR (HR=1.310), tumor 
multiplicity at TACE (HR=1.614), and higher total bilirubin lev-
el at CR (HR=1.429) were significantly associated with a short-
er OS. Previous history of complete HCC resection was inde-
pendently associated with longer OS (HR=0.713) (Table 4). In 
a subgroup with AFP >10 ng/mL at TACE, AFP non-responders 
Table 2. PFS and OS after TACE
Patient group Survival
AFP ≤20 ng/mL at CR
(n=694, 78.0%)





Mean (95% CI) 34.4 (31.1–37.6) 36.7 (32.8–40.5) 25.4 (19.8–30.9)
<0.001
Median (IQR) 16.3 (7.9–41.6) 17.7 (9.1–46.4) 11.2 (6.5–26.9)
OS
Mean (95% CI) 77.8 (73.0–82.5) 80.4 (74.8–85.9) 67.3 (58.6–75.9)
0.003







Patients with AFP >10 ng/mL 
  at TACE (n=471)
PFS
Mean (95% CI) 30.1 (26.1–34.0) 33.0 (28.2–37.7) 18.3 (14.7–21.9)
0.001
Median (IQR) 13.7 (7.3–36.5) 15.5 (7.7–39.6) 10.5 (6.7–20.8)
OS
Mean (95% CI) 71.7 (65.9–77.4) 76.3 (69.6–83.1) 53.1 (45.4–60.9)
0.001
Median (IQR) 56.1 (31.5–95.6) 61.8 (35.7–103.6) 41.4 (26.1–75.8)
TACE, transarterial chemoembolization; AFP, alpha-fetoprotein; CR, complete response; PFS, progression-free survival; OS, overall survival; CI, confidence inter-
val; IQR, interquartile range.
*AFP responder: patients with AFP >10 ng/mL at TACE and a >50% reduction in AFP or AFP ≤10 ng/mL at CR, †AFP non-responder: patients with AFP >10 ng/mL 
at TACE and a ≤50% reduction in AFP and AFP >10 ng/mL at CR.
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were independently associated with shorter OS (HR=1.406), 
together with tumor multiplicity at TACE (HR=1.463) and high-
er total bilirubin level at CR (HR=1.485). Previous HCC resec-
tion was still associated with longer OS (HR=0.761) in this 
subgroup (Table 4 and Supplementary Table 2, only online).
Subgroup analysis in patients with BCLC stage B HCC
When 112 patients with BCLC stage B HCC were selected (Sup-
plementary Table 3, only online), patients with elevated AFP 
levels at CR (>20 ng/mL, n=80, 71.4%) showed shorter PFS 
(median 6.5 months vs. 13.5 months, p=0.002) and OS (median 
28.2 months vs. 52.4 months, p=0.142), whereas AFP respond-
ers (n=42, 59.8%) did not have longer favorable PFS and OS, 
compared to non-responders (n=25, 37.3%, p=0.277 and 0.882) 
(Supplementary Table 4, only online). Multivariate analysis 
showed that high AFP at CR (>20 ng/mL) was independently 
associated only with shorter PFS (HR=2.287, p<0.001) (Sup-
plementary Tables 5 and 6 only online).
DISCUSSION
In this study, we evaluated whether AFP levels at CR achieve-
ment after TACE have prognostic value, based on the fact that 
Fig. 1. Kaplan-Meier analysis for the subgroup by AFP at CR (>20 ng/mL) for PFS (A) and OS (B), and for the subgroup by AFP responder for PFS (C) and 
OS (D). AFP, alpha-fetoprotein; CR, complete response; PFS, progression-free survival; OS, overall survival.
No. at risk
AFP ≤20 ng/mL 694 203 77 37 20 7 0
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not all patients who achieve radiological CR show AFP levels 
in the normal range. To this aim, we retrospectively analyzed 
890 patients with HCC who achieved CR after TACE. Com-
pared with previous studies that recruited mostly HCC patients 
with elevated AFP levels,16,17,19,20 our study population had rel-
atively small tumors (median 2.0 cm) with mostly BCLC stage 
0 and A tumors (81.4%), which might be associated with the 
higher rate of CR achievement after TACE. In addition, among 
patients with elevated AFP levels at TACE, 359 (76.2%) showed 
AFP response, which is similar or higher to the results from 
previous studies.20-24 In multivariate analysis, patients with el-
evated AFP at CR and AFP non-responders were independently 
associated with poor outcomes (HR=1.403 and 1.375 for short-
er PFS, and HR=1.310 and 1.406 for shorter OS, respectively). 
Our study has several clinical implications. First, we showed 
that both absolute AFP levels at CR and changes in AFP levels 
between TACE and CR achievement have a prognostic role in 
predicting disease progression and OS. To date, AFP has been 
shown to be quantitatively correlated with tumors and to be 
associated with aggressive behavior and microvascular inva-
sion.25 Accordingly, AFP has been used as a biomarker for HCC, 
having both diagnostic and prognostic roles. Further, post-
treatment AFP response has also been found to predict prog-
nosis.15-17,20,26-32 In the present study, although the median AFP 
level at CR achievement after TACE was within the normal 
range (6.36 ng/mL), approximately 22% of the patients (n=196 
of 890) still had elevated AFP (>20 ng/mL) even after achieving 
a CR. This could be explained by the presence of residual or 
satellite cancer cells resistant to TACE that were not detected 
by conventional imaging studies, thus leading to early recur-
rence with aggressive tumor behavior.
Second, our finding that post-treatment AFP response was 
a favorable predictor of longer PFS and OS is supported by 
other studies, which defined post-treatment AFP response dif-
ferently: reduction of 20% to 50% in AFP levels from baseline 
according to the characteristics of cancer and treatment mo-
dalities among patients with elevated AFP level prior to treat-
ments.16,17,20,31 Regardless of the varying study designs, patients 
with an AFP response consistently showed better survival out-
comes than their counterparts. However, this definition might 
have some disadvantage in that it is difficult to apply directly 
to patients with low baseline AFP levels, and the effect of mi-
nor AFP changes on prognosis could be ignored. Therefore, we 
evaluated the impact of AFP normalization as an additional 
definition of AFP response. In our study, AFP response was de-
fined not only as a 50% reduction in AFP levels from baseline, 
but also as its normalization (<10 ng/mL) at CR achievement. 
Similar with previous studies, using this definition, we found 
that patients with an AFP response showed better outcomes of 
prolonged PFS (median 15.5 months vs. 10.5 months) and OS 
(median 61.8 months vs. 41.4 months), compared to patients 
with no AFP response. An unfavorable AFP response might 
represent insufficient tumor necrosis by hypoxic damage 
through TACE more sensitively than post-treatment imaging 
studies, especially when imaging studies cannot provide any 
Table 3. Multivariate Analysis to Identify Independent Predictors for 





p value Hazard ratio (95% CI)
All (n=890)
BCLC stage B/C vs. 0/A <0.001   0.053 1.252 (0.997–1.572)
Tumor multiplicity <0.001 <0.001 1.518 (1.262–1.827)
Serum albumin, g/dL   0.004   0.096 0.875 (0.748–1.024)
AFP >20 ng/mL at CR <0.001 <0.001 1.403 (1.167–1.686)
Subgroup with AFP level >10 ng/mL at TACE (n=471)
BCLC stage B/C vs. 0/A <0.001   0.033 1.377 (1.027–1.847)
Tumor multiplicity <0.001   0.033 1.317 (1.022–1.697)
AFP non-responder*   0.001   0.011 1.375 (1.077–1.756)
CR, complete response; CI, confidence interval; BCLC, Barcelona Clinic Liver 
Cancer; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization.
*AFP non-responder: patients with AFP >10 ng/mL at TACE and a ≤50% re-
duction in AFP and AFP >10 ng/mL at CR.
Table 4. Multivariate Analysis to Identify Independent Predictors for 









Age >70 (yr)   0.016   0.127 1.222 (0.944–1.582)
Hepatitis B   0.010   0.281 0.844 (0.619–1.150)
Hepatitis C   0.020   0.903 1.023 (0.713–1.468)
Liver cirrhosis   0.034   0.951 1.008 (0.794–1.279)
Recurrent HCC
  after complete resection
<0.001   0.003 0.713 (0.569–0.893)
BCLC stage B/C vs. 0/A   0.017   0.943 1.010 (0.762–1.340)
Tumor multiplicity <0.001 <0.001 1.666 (1.348–2.058)
Aspartate 
  aminotransferase (IU/L)
  0.004   0.589 1.000 (0.999–1.001)
Serum albumin (g/dL) <0.001   0.077 0.820 (0.658–1.021)
Total bilirubin (mg/dL) <0.001 <0.001 1.441 (1.268–1.638)
Prothrombin time (INR)   0.001   0.480 1.269 (0.655–2.460)
AFP >20 ng/mL at CR   0.003   0.027 1.284 (1.028–1.604)
Subgroup with AFP level >10 ng/mL at TACE (n=471)
Recurrent HCC 
  after complete resection
  0.001   0.002 0.761 (0.608–0.951)
BCLC stage B/C vs. 0/A   0.003   0.965 0.992 (0.696–1.415)
Tumor multiplicity   0.003   0.006 1.463 (1.113–1.923)
Serum albumin (g/dL)   0.003   0.586 0.924 (0.696–1.228)
Total bilirubin (mg/dL) <0.001 <0.001 1.485 (1.291–1.708)
Prothrombin time (INR)   0.001   0.654 0.809 (0.320–2.046)
AFP non-responder*   0.001   0.015 1.424 (1.070–1.895)
CR, complete response; CI, confidence interval; HCC, hepatocellular carcinoma; 
BCLC, Barcelona Clinic Liver Cancer; INR, international normalized ratio; AFP, al-
pha-fetoprotein; TACE, transarterial chemoembolization.
*AFP non-responder: patients with AFP >10 ng/mL at TACE and a ≤50% re-
duction in AFP and AFP >10 ng/mL at CR.
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more information regarding tumor viability.33
Third, along with AFP levels at CR and changes therein from 
baseline, tumor multiplicity was also independently associat-
ed with prognosis, in spite of CR achievement. To date, various 
tumor-staging systems have already incorporated tumor mul-
tiplicity, which has also been studied as a part of a prognostic 
scoring systems for TACE in several studies.32,34-36 In our study, 
the predictive value of tumor multiplicity at the time of TACE 
was maintained even after CR achievement. This might be due 
to a higher possibility for remnant viable tumors in the treated 
lesion, which were undetected using radiological assessment, 
or small intrahepatic tumors. In addition, BCLC stage B and C 
tended to be associated with shorter PFS, compared to BCLC 
stage 0-A (HR=1.252, p=0.053).
Fourth, based on the results of our study, we cautiously sug-
gest that further advanced surveillance strategies are required, 
even after CR achievement after TACE. To date, various scoring 
systems have been proposed to stratify patients with different 
prognoses after TACE. While it might be clinically infeasible to 
use complex scoring systems, using post-treatment AFP levels 
and changes therein as a biologic response surrogate after TACE, 
even after CR achievement, could be a simple and more intui-
tive way of aiding clinical decision-making. For patients with 
elevated AFP or poor AFP response after CR, surveillance us-
ing MRI,37 scheduled secondary angiography,10 and additional 
therapy, such as ablation or stereotactic radiotherapy, might 
be helpful for early detection of hidden lesions.38,39
Although we focused on the time point of CR after one or 
several TACEs as our baseline, we collected additional infor-
mation regarding the number of TACE sessions to achieve CR 
status. Most patients achieved CR through one (83.5%) or two 
TACE sessions (14.0%). Patients who achieved CR after multi-
ple sessions of TACE had a significantly shorter OS than those 
with one TACE session (HR=1.730, p=0.002), which was sup-
ported by a previous study showing that CR at first TACE was 
the most robust predictor for favorable OS.8 However, single 
or multiple TACE sessions did not influence PFS (p=0.177), 
probably due to the significantly skewed distribution of the 
number of TACE sessions to achieve CR.
Several unresolved issues remain in our study. First, since 
most HCC diagnoses lacked histologic evaluations according 
to the current guidelines,1,4 the correlations between tumor 
differentiation and AFP levels were not identified.33 Second, 
the retrospective setting of the present study limited the eval-
uation of other potential risk factors, such as recurrent type of 
HCC (intrahepatic vs. intrahepatic and extrahepatic) and des-
gamma carboxyprothrombin (DCP), which is another well-
demonstrated serum marker for HCC prognosis. Although a 
previous study noted the poor performance of DCP response 
on prognosis after TACE,20 identifying its efficacy in patients 
with a CR may be of additional value for clinicians. Third, due 
to the retrospective nature of our study, it remains unclear why 
most patients with early HCC did not receive resection or ab-
lation in our study. Old age, comorbidity, or preference to re-
ceive non-surgical treatment might be potential reasons for 
this. Indeed, in our institute, a significant proportion of patients 
with early stage HCC received TACE, instead of resection or 
ablation.2 Fourth, AFP and its response showed an insufficient 
association with outcomes in a subgroup with BCLC stage B, 
probably due to the skewed distribution of BCLC stages in our 
study. High AFP level was significantly associated with PFS 
among patients classified as BCLC stage B [n=112 (12.6%)]. 
However, AFP and its response were insufficiently associated 
with OS, while serum bilirubin still was found to influence the 
outcome. The significantly small distribution of this subgroup 
probably biased the association, especially in patients with 
AFP level >10 ng/mL at TACE [n=67 (7.5%)]. Fifth, this study 
could not evaluate the effect of disease progression after HCC 
relapse and subsequent treatments on patient prognosis. Fi-
nally, the influence of detailed technical variables, such as ori-
gin of the feeding vessel and procedure time, were not investi-
gated.
In conclusion, high AFP and AFP non-responder were inde-
pendently associated with poor outcomes after achieving a CR 
after TACE. Thus, assessment of AFP levels after achieving a 
CR after TACE might provide further detailed prognostication, 
even when radiological CR is achieved.
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